Drug intelligence / Profile preview

SDL-003

Development stage: Preclinical
Lead developer: Synthetic Design Lab
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SDL-003 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Synthetic Design Lab for the treatment of solid tumors. The asset is part of a pipeline generated using the company's AI-driven 'Synthetic Design' platform, which aims to optimize the therapeutic index of ADCs by engineering specific antibody-linker-payload combinations. As of 2024, SDL-003 remains in the discovery/preclinical phase, and its specific molecular target has not been publicly disclosed by the sponsor.

Beyond the preview

Go deeper on SDL-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SDL-003.

Explore the full profile